Advertisement

Product › Details
semaglutide (NN9924)
![]() |
Next higher product group | GLP-1 analogue |
![]() |
Status | 2017-12-05 registration start |
![]() |
Organisation | Novo Nordisk A/S |
Group | Novo Group (Group) | |
Record changed: 2020-12-15 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for semaglutide (NN9924)
- [1] Emisphere Technologies, Inc.. (11/6/20). "Press Release: Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion". Roseland, NJ....
- [2] Gilead Sciences, Inc.. (4/12/19). "Press Release: Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH". Foster City & Bagsvaerd....
- [3] Novo Nordisk A/S. (8/20/18). "Press Release: Oral Semaglutide Provides Superior HbA1c and Weight Reductions versus Placebo in People with Type 2 Diabetes and Renal Impairment in the PIONEER 5 trial". Bagsvaerd....
- [4] Novo Nordisk A/S. (8/8/18). "Press Release: Novo Nordisk’s Operating Profit Decreased by 8% in Danish Kroner and Increased by 4% in Local Currencies in the First Six Months of 2018"....
- [5] Novo Nordisk A/S. (12/15/17). "Press Release: Ozempic (semaglutide) Recommended for Approval by the European Regulatory Authorities". Bagsvaerd....
- [6] Novo Nordisk A/S. (12/5/17). "Press Release: Ozempic (semaglutide) Approved in the US". Bagsvaerd....
- [7] Novo Nordisk A/S. (8/16/17). "Press Release: Semaglutide Superior to Dulaglutide on Glucose Control and Weight Loss in People with Type 2 Diabetes in SUSTAIN 7". Bagsvaerd....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top